Public Employees Retirement System of Ohio Sells 5,276 Shares of Edwards Lifesciences Co. (NYSE:EW)

Public Employees Retirement System of Ohio decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 294,926 shares of the medical research company's stock after selling 5,276 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.05% of Edwards Lifesciences worth $21,833,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter worth $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the fourth quarter worth about $27,000. Millstone Evans Group LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $30,000. Finally, Catalyst Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $54,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president now directly owns 33,496 shares of the company's stock, valued at $2,514,879.68. This represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This trade represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,442 shares of company stock valued at $4,025,799 in the last quarter. Insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Down 0.0%

Shares of NYSE EW traded down $0.01 during trading hours on Friday, hitting $77.72. The stock had a trading volume of 2,871,498 shares, compared to its average volume of 5,158,722. The firm's 50-day moving average price is $73.22 and its two-hundred day moving average price is $72.33. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25. The company has a market capitalization of $45.59 billion, a P/E ratio of 11.16, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the company posted $0.66 EPS. The firm's revenue was up 6.2% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EW. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Robert W. Baird upped their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Finally, Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.